Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 Jul 31, 2025 04:05PM
Relay Therapeutics (RLAY) appoints Claire Mazumdar to Board Jun 11, 2025 04:07PM
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors Jun 11, 2025 04:05PM
Relay Therapeutics (RLAY) Announces Updated Data for RLY-2608 + Fulvestrant Jun 2, 2025 07:02AM
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Jun 2, 2025 07:00AM
View Older Stories

May 29, 2025 04:05PM Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 8, 2025 04:05PM Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 5, 2025 04:05PM Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Apr 28, 2025 04:05PM Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Feb 26, 2025 04:05PM Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Feb 24, 2025 04:05PM Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Feb 19, 2025 04:05PM Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
Jan 7, 2025 04:05PM Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Dec 11, 2024 06:00AM Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Dec 9, 2024 04:05PM Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Dec 3, 2024 08:01AM Relay Therapeutics (RLAY) and Elevar Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Dec 3, 2024 08:01AM Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Dec 3, 2024 08:00AM Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Nov 7, 2024 04:05PM Relay Therapeutics to Participate in Upcoming Investor Conferences
Nov 6, 2024 04:05PM Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Oct 30, 2024 04:05PM Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Sep 9, 2024 06:57AM Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Sep 9, 2024 06:55AM Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Sep 6, 2024 04:05PM Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
Aug 6, 2024 04:05PM Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Jul 30, 2024 04:05PM Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Jun 6, 2024 07:00AM Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
Jun 6, 2024 07:00AM Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
Jun 5, 2024 04:05PM Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
May 21, 2024 04:05PM Relay Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2024 08:30AM Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 2, 2024 04:05PM Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Apr 25, 2024 04:05PM Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
Apr 11, 2024 04:05PM Relay Therapeutics to Participate in Upcoming Investor Conferences
Feb 26, 2024 04:05PM Relay Therapeutics to Participate in Three Upcoming Investor Conferences
Feb 22, 2024 04:05PM Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Feb 15, 2024 04:05PM Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
Feb 1, 2024 04:05PM Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Jan 8, 2024 07:02AM Relay Therapeutics (RLAY) Announces 2.5M Share Placement at $12/sh
Jan 8, 2024 07:00AM Relay Therapeutics Announces $30 Million Private Placement Financing
Jan 2, 2024 04:05PM Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Nov 7, 2023 04:05PM Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
Nov 2, 2023 04:05PM Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
Oct 26, 2023 04:05PM Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
Oct 12, 2023 04:05PM Relay Therapeutics (RLAY) Reports Initial RLY-4008 Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Oct 12, 2023 04:05PM Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Sep 18, 2023 04:05PM Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aug 8, 2023 04:02PM Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
Aug 1, 2023 04:05PM Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
May 25, 2023 05:03PM Relay Therapeutics (RLAY) Announces Full Dose Escalation Data for RLY-4008
May 25, 2023 05:01PM Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
May 24, 2023 04:05PM Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 4, 2023 04:05PM Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
Apr 27, 2023 04:05PM Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
Apr 27, 2023 04:05PM Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
View Older Stories